Skip to content
lifestyle.ribbon.co
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Astellas Pharma Inc.
Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
August 24, 2026